Cargando…
To stop or not to stop: what should we be doing with biologic DMARDs when patients undergo orthopaedic surgery?
Autores principales: | van Duren, Bernard H, Wignall, Alice, Rangan, Amar, Coates, Laura, Pandit, Hemant, Mankia, Kulveer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493102/ https://www.ncbi.nlm.nih.gov/pubmed/34622125 http://dx.doi.org/10.1093/rap/rkab057 |
Ejemplares similares
-
When and how should we use imaging in individuals at risk of rheumatoid arthritis?
por: Harnden, Kate, et al.
Publicado: (2022) -
Should we stop methotrexate or not for vaccination?
por: Durez, Patrick, et al.
Publicado: (2023) -
When Should Statins Be Stopped?
por: Bibi, Mário, et al.
Publicado: (2021) -
‘Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?’
por: Goodman, Susan M, et al.
Publicado: (2020) -
P02 When should we stop the antiresorptive medications in patients with osteoporosis?
por: Mohareb, Marwa, et al.
Publicado: (2023)